What do patients experience with Cosentyx treatment?
Cosentyx, also known as secukinumab, is a biologic medication used to treat psoriasis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. [1] While individual experiences may vary, many patients who use Cosentyx report significant improvements in their symptoms. [2]
How long does it take for Cosentyx to work?
Clinical trials have shown that Cosentyx can start to work within 16 weeks, with some patients experiencing significant improvements as early as 4-6 weeks. [3] However, it's essential to note that everyone's body is different, and the pace of treatment can vary.
Common side effects of Cosentyx: What are patients experiencing?
Patients may experience some common side effects, including: injection site reactions (such as pain, redness, or swelling at the injection site), upper respiratory tract infections (such as a sore throat, runny nose, or cough), and fatigue. [4] These side effects are usually mild to moderate and temporary.
Why is Cosentyx prescribed over other treatments?
Cosentyx is a biologic medication, meaning that it targets specific proteins in the body that contribute to psoriasis symptoms. [5] By targeting these proteins, Cosentyx can provide long-lasting relief from psoriasis symptoms. Additionally, studies have shown that Cosentyx can be effective against more severe psoriasis cases that may not respond to other treatments. [6]
Patient concerns: Is Cosentyx worth it?
While Cosentyx can be an effective treatment option, some patients may have concerns about its cost, potential side effects, or effectiveness. [7] Patients should discuss their concerns with their doctor to determine if Cosentyx is the right treatment option for them.
Is there a risk of withdrawal or rebound with Cosentyx?
In clinical trials, patients who stopped taking Cosentyx experienced a gradual decrease in its effectiveness but no instances of withdrawal symptoms. However, patients who stopped taking the medication may experience a rebound effect, where their psoriasis symptoms worsen temporarily before stabilizing. [8]
When does exclusivity expire for Cosentyx?
Patent exclusivity for Cosentyx, a biologic drug developed by Novartis, may expire around 2027. [9] This may lead to increased competition for the medication and the potential for more affordable treatment options.
Sources:
[1] Novartis. (n.d.). Cosentyx. Retrieved from https://www.novartis.com/our-products/dermatology/cosentyx
[2] Cosentyx patient reviews. (n.d.). Retrieved from https://www.cosentyx.com/en/patient-experience
[3] European Medicines Agency. (2017). Cosentyx (secukinumab). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
[4] Cosentyx prescribing information. (n.d.). Retrieve from https://www.cosentyx.com/assets/documents/CosentyxPrescribingInformation.pdf
[5] National Psoriasis Foundation. (n.d.). Psoriasis treatment: Biologics. Retrieved from https://www.psoriasis.org/ treatment/biologics
[6] National Psoriasis Foundation. (n.d.). Psoriasis treatment: What's right for me? Retrieved from https://www.psoriasis.org/treatment/what's-right-for-me
[7] Cosentyx patient concerns. (n.d.). Retrieved from https://www.cosentyx.com/patient-concerns
[8] European Medicines Agency. (2017). Cosentyx (secukinumab). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
[9] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab). Retrieved from https://drugpatentwatch.com/drug/Cosentyx
DrugPatentWatc.com is a valuable resource for information on patent exclusivity, regulatory status, and other information relevant to the drug market.